Monday, August 26, 2013

Sanofi Pasteur's Fluzone High-Dose Vaccine results - and PMG Research!

Sanofi Pasteur - the vaccines division of Sanofi - announced today that its Fluzone High-Dose vaccine was significantly more effective than the standard dose Fluzone vaccine in preventing influenza in adults 65 and older. Fluzone High-Dose vaccine was licensed in the United States by the Food and Drug Administration (FDA) in December 2009 under an accelerated approval pathway based on the vaccine's safety profile and superior immunogenicity compared to Fluzone vaccine. As a requirement of the accelerated approval, however, Sanofi Pasteur conducted this large-scale, two-season, confirmatory efficacy trial in more than 30,000 adults over the age of 65. You can read the press release from Sanofi Pasteur here.

Nine PMG Research sites participated in this study last year, enrolling 1,505 volunteers in 13 days and exceeding the enrollment goal for the sites. Eight sites participated in 2011, enrolling 1,218 volunteers in 14 days. We even enrolled 445 volunteers on one Sunday! 

If you are interested in participating in our upcoming studies for the flu vaccine, stay tuned! We’ll be sending out information for all ages as soon as it is available. You can also complete the Contact Us form located here, and we will let you know when the studies begin.

Thank you to all our past, current, and future volunteers who participate not only in our flu vaccine studies, but in all of PMG Research’s studies. Without you, PMG and companies like Sanofi Pasteur wouldn’t be able to share great news like this!

No comments :

Post a Comment

Subscribe Via Email